Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial by Fizazi, Karim, Prof, Pagliaro, Lance, Prof, Laplanche, Agnes, MD, Fléchon, Aude, MD, Mardiak, Josef, Prof, Geoffrois, Lionnel, MD, Kerbrat, Pierre, Prof, Chevreau, Christine, MD, Delva, Remy, MD, Rolland, Frederic, MD, Theodore, Christine, MD, Roubaud, Guilhem, MD, Gravis, Gwenaëlle, MD, Eymard, Jean-Christophe, MD, Malhaire, Jean-Pierre, MD, Linassier, Claude, Prof, Habibian, Muriel, Martin, Anne-Laure, Journeau, Florence, Reckova, Maria, MD, Logothetis, Christopher, Prof, Culine, Stephane, Prof

Get full text

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial by Négrier, Sylvie, Prof, Gravis, Gwenaëlle, MD, Pérol, David, MD, Chevreau, Christine, MD, Delva, Rémy, MD, Bay, Jacques-Olivier, Prof, Blanc, Ellen, MSc, Ferlay, Céline, MSc, Geoffrois, Lionnel, MD, Rolland, Frédéric, MD, Legouffe, Eric, MD, Sevin, Emmanuel, MD, Laguerre, Brigitte, MD, Escudier, Bernard, MD

Get full text

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial by Gravis, Gwenaelle, Dr, Fizazi, Karim, Prof, Joly, Florence, Prof, Oudard, Stéphane, Prof, Priou, Franck, MD, Esterni, Benjamin, MSc, Latorzeff, Igor, MD, Delva, Remy, MD, Krakowski, Ivan, Prof, Laguerre, Brigitte, MD, Rolland, Fréderic, MD, Théodore, Christine, MD, Deplanque, Gael, MD, Ferrero, Jean Marc, Prof, Pouessel, Damien, MD, Mourey, Loïc, MD, Beuzeboc, Philippe, MD, Zanetta, Sylvie, MD, Habibian, Muriel, Berdah, Jean François, MD, Dauba, Jerome, MD, Baciuchka, Marjorie, MD, Platini, Christian, MD, Linassier, Claude, Prof, Labourey, Jean Luc, MD, Machiels, Jean Pascal, Prof, El Kouri, Claude, MD, Ravaud, Alain, Prof, Suc, Etienne, MD, Eymard, Jean Christophe, MD, Hasbini, Ali, MD, Bousquet, Guilhem, MD, Soulie, Michel, Prof

Get full text

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised cont... by Fizazi, Karim, Prof, Faivre, Laura, Lesaunier, François, MD, Delva, Remy, MD, Gravis, Gwenaëlle, MD, Rolland, Frédéric, MD, Priou, Frank, MD, Ferrero, Jean-Marc, Prof, Houede, Nadine, MD, Mourey, Loïc, MD, Theodore, Christine, MD, Krakowski, Ivan, MD, Berdah, Jean-François, MD, Baciuchka, Marjorie, MD, Laguerre, Brigitte, MD, Fléchon, Aude, MD, Ravaud, Alain, Prof, Cojean-Zelek, Isabelle, MD, Oudard, Stéphane, Prof, Labourey, Jean-Luc, MD, Chinet-Charrot, Paule, MD, Legouffe, Eric, MD, Lagrange, Jean-Léon, Prof, Linassier, Claude, Prof, Deplanque, Gaël, MD, Beuzeboc, Philippe, MD, Davin, Jean-Louis, MD, Martin, Anne-Laure, PharmD, Habibian, Muriel, Laplanche, Agnès, MD, Culine, Stéphane, Prof

Get full text

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multi... by Wood, Christopher, MD, Srivastava, Pramod, MD, Bukowski, Ronald, MD, Lacombe, Louis, MD, Gorelov, Andrei I, MD, Gorelov, Sergei, MD, Mulders, Peter, MD, Zielinski, Henryk, MD, Hoos, Axel, MD, Teofilovici, Florentina, MD, Isakov, Leah, MS, Flanigan, Robert, MD, Figlin, Robert, MD, Gupta, Renu, MD, Escudier, Bernard, MD

Get full text